Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)

NCT02981368 is registered in ClinicalTrials.gov with Progenics Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02981368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02981368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Lead sponsor
Progenics Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2016
Completion date
July 31, 2018
Enrollment
385 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer